Sana Biotechnology (NASDAQ:SANA) climbed over 200% on Wednesday following a sharp rally in the post-market yesterday in ...

Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...

Roche's strategic acquisition of Poseida Pharmaceuticals positions them as a leader in the allogeneic cell therapy market.

Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43rd Annual J.P.

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

Sana Biotechnology Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -68.45%. The profit margin, also known as the revenue ratio or gross profit ratio ...

Dave & Buster's (PLAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances.

With Alonso continuing to explore free agency, it's becoming more clear what the slugger is looking for. The New York Post's Jon Heyman reports Wednesday that the gulf between the Mets and Alonso ...